Disclosure Of First-Time Adoption [Text Block]

Innate Pharma - Filing #2821023

Concept	2020-01-01 to 2020-12-31	As at 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	As at 2020-12-31	2020-01-01 to 2020-12-31	As at 2020-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	2019-01-01 to 2019-12-31	As at 2019-12-31	2019-01-01 to 2019-12-31	2019-01-01 to 2019-12-31	As at 2019-12-31	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2019-01-01	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31	As at 2018-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	—	156 476 EUR	63 984 EUR	—	3 950 EUR	—	372 131 EUR	355,000 EUR	—	155 976 EUR	20 759 EUR	369 617 EUR	217 416 EUR	134 912 EUR	—	3 941 EUR	—	—	472,000 EUR	3 197 EUR	299 932 EUR	137 961 EUR	167 119 EUR	3 049 EUR	1 099 EUR	121,000 EUR	299 932 EUR	167 240 EUR	1 099 EUR	3 049 EUR	3 197 EUR	137 840 EUR	121,000 EUR
Comprehensive income	63 962 EUR	—	—	63 984 EUR	—	805,000 EUR	—	—	827,000 EUR	—	—	—	—	—	20 132 EUR	—	627,000 EUR	20 759 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Profit (loss)	63 984 EUR	—	—	63 984 EUR	—	—	—	—	—	—	—	—	—	—	20 759 EUR	—	—	20 759 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—